Structure-based design and synthesis of macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors.

The hydroxyethylene octapeptide inhibitor OM99-2 served as starting point to create the tripeptide inhibitor 1 and its analogues 2a and b. An X-ray co-crystal structure of 1 with BACE-1 allowed the design and syntheses of a series of macrocyclic analogues 3a-h covalently linking the P1 and P3 side-chains. These inhibitors show improved enzymatic potency over their open-chain analogue. Inhibitor 3h also shows activity in a cellular system.

[1]  J. Wood,et al.  Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. , 2000, Chemistry & biology.

[2]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[3]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[4]  A. Barrett.  Cathepsin D. Purification of isoenzymes from human and chicken liver. , 1970, The Biochemical journal.

[5]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Alice Stanton,et al.  Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.

[7]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[8]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[9]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[10]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[11]  A. Alzheimer.  über eigenartige Krankheitsfälle des späteren Alters , 1911 .

[12]  D. Hazuda,et al.  Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[13]  M. Katharine Holloway,et al.  Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model. , 2006 .

[14]  R. Grubbs,et al.  Increased ring closing metathesis activity of ruthenium-based olefin metathesis catalysts coordinated with imidazolin-2-ylidene ligands , 1999 .

[15]  A. Simon,et al.  Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[16]  J. Hardy,et al.  Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). , 1990, Science.

[17]  Lin Hong,et al.  Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design† , 2001 .

[18]  A. Tomasselli,et al.  Targeting the HIV-protease in AIDS therapy: a current clinical perspective. , 2000, Biochimica et biophysica acta.

[19]  V. Laurent-Matha,et al.  Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. , 2006, Cancer letters.

[20]  M. Martín-Pastor,et al.  Design and synthesis of a novel class of sugar-peptide hybrids: C-linked glyco beta-amino acids through a stereoselective "acetate" Mannich reaction as the key strategic element. , 2002, Journal of the American Chemical Society.

[21]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[22]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[23]  Stephen Hanessian,et al.  Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. , 2005 .

[24]  Colin McMartin,et al.  QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..

[25]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[26]  P. Reinemer,et al.  Macrocyclic Statine‐Based Inhibitors of BACE‐1 , 2007, Chembiochem : a European journal of chemical biology.

[27]  Arun K. Ghosh,et al.  Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase) , 2001 .

[28]  D. Timm,et al.  Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex. , 2006, Bioorganic & medicinal chemistry letters.

[29]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[30]  Lin Hong,et al.  Structure-based design of cycloamide–urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase) , 2005 .

[31]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[32]  Martin J Scanlon,et al.  Conformationally constrained macrocycles that mimic tripeptide beta-strands in water and aprotic solvents. , 2002, Journal of the American Chemical Society.

[33]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.